Matthew is a transactional attorney who leverages his corporate experience and deep industry knowledge to help clients across the life sciences and technology sectors execute a broad spectrum of transactions. He represents parties on all sides of financing transactions, private placements, and public offerings and counsels life sciences companies on a variety of commercial agreements. Clients ranging from start-ups to public corporations also rely on Matthew’s advice on matters involving Canadian corporate and securities law.
Matthew has extensive experience advising issuers, investors, and dealers in public and private corporate finance transactions, including venture capital financings, private placements, and public offerings, including IPOs. He also regularly works with acquirers and targets undertaking public or private M&A transactions, such as share acquisitions, plans of arrangement, and other business combinations. In addition, Matthew provides guidance to life sciences clients on the full spectrum of their commercial agreements, helping them negotiate and set up IP licensing transactions, distribution arrangements, and research and collaboration agreements.
Prior to joining Mintz, Matthew was counsel at a major Canadian law firm, where he advised clients across the life sciences and technology sectors on capital markets transactions, private placements, venture capital financing, and commercial agreements. Earlier, while working as a senior research assistant at the University of Western Ontario, Faculty of Law, he led a research project focused on Canada’s Securities Transfer Act. In that role, he also assisted with updating the publications Secured Transactions in Personal Property in Canada, Annotated Ontario Personal Property Security Act, and Canadian Commercial Reorganization: Preventing Bankruptcy.
Experience
Featured Experience:
- Advised OmniaBio in connection with its launch, including its spinout from the Centre for Commercialization of Regenerative Medicine (CCRM), its C$30 million sale of a 39% interest to Medipost Co., C$40 million in government funding by the Government of Ontario, and up to C$100 million convertible note financing and the negotiation of its new C$580 million cell and gene therapy facility.
- Advised Thornhill Medical in negotiating manufacturing and supply agreements to make and deliver mobile compact ventilator systems as part of the Canadian government's response to fight COVID-19.
- Represented 7D Surgical, a medical device company developing advanced optical and machine-vision technologies for surgical navigation, in its $110 million sale to SeaSpine Holdings Corporation, a global medical technology company developing surgical solutions for the treatment of spinal disorders.
Transactional and Investment Matters:
- Represented Triumvira Immunologics, a biotechnology company developing and commercializing novel cell therapies to treat cancer,
- in its $55 million Series A financing led by Northpond Ventures and Leaps by Bayer, the impact investment unit of Bayer AG.
- in its $45 million Series A financing extension, bringing the total round to approximately $100 million.
- Represented Conavi Medical in the $20 million financing of Novasight Hybrid System, an imaging platform to support minimally invasive heart procedures.
- Advised a digital wound care company Swift Medical
- in its $35 million (C$44 million) Series B financing led by Virgo Investment Group LLC to incorporate artificial intelligence (AI) in wound care delivery.
- in its $12 million Series A financing led by Data Collective.
- Represented 7D Surgical, a medical device company developing advanced optical and machine-vision technologies for surgical navigation,
- in its $110 million sale to SeaSpine Holdings Corporation, a global medical technology company developing surgical solutions for the treatment of spinal disorders.
- in multiple private placements to fund and support the commercial launch of its FDA 510(k) approved Machine-vision Image Guided Surgery (MvIGS) system.
- Advised Versant Ventures, OrbiMed, F-Prime Capital, and Sixty Degree Capital in the $80 million Series D financing of Turnstone Biologics Corp, a clinical-stage biotechnology company developing cancer immunotherapies.
- Advised OrbiMed
- as the lead investor in the $41 million Series B financing of Turnstone Biologics Inc.
- in a $135 million multi-series investment in Enobia Pharma Inc. (now Alexion Montréal Corp.).
- Advised OrbiMed and other investors in their investment in the $42 million Series C financing of Turnstone Biologics Inc.
- Represented Isologic Innovative Radiopharmaceuticals
- in its acquisition of commercial distribution of diagnostic FDG (fluorodeoxyglucose) molecules from the Centre for Probe Development and Commercialization.
- in its $10 million acquisition of the radiopharmacy division of Lantheus Medical Imaging, Inc.
- Advised Synaptive Medical
- in a US$40 million investment by Export Development Canada.
- in a $17 million preferred share investment by Sensegain Group, a leading asset management firm in China.
- in its $25 million preferred share financing and concurrent C$50 million debt-to-equity conversion.
- Represented Northern Biologics
- in the global sale of its lead asset, a clinical-stage immuno-oncology antibody, to a subsidiary of AstraZeneca plc.
- in its sale of two immuno-oncology programs to Boehringer Ingelheim International GmbH.
- Represented Riot Games in its acquisition of computer game developer Hypixel Studios.
- Advised Hikma Ventures, the investment arm of Hikma Pharmaceuticals PLC, as the lead investor in Winterlight Labs Inc.'s C$5.6 million Series A financing.
- Represented MolecuLight,
- in its financing transaction with BDC Capital and iGan Ventures.
- in its US$10 million loan from SWK Holdings to support global commercial expansion.
- in the sale of its clinical oncology business to photonamic GmbH & Co. KG.
- in its $7.5 million loan from Oxford Finance to fund the expansion of Moleculight i:X, a portable device used to digitally measure bacteria in chronic wounds to optimize treatment.
- Advised Kalytera Therapeutics, a pioneer in next-generation cannabinoid therapeutics,
- in its C$15 million multi-tranche private placement of common shares.
- in its C$6.76 million public offering of units.
- Represented B. Braun Melsungen in its acquisition of a majority interest in Sterinova Inc., a drug delivery and medical device company.
- Represented Merus Labs in its C$342 million sale to Norgine B.V.
- Advised LEAGUE in its C$33 million Series A venture capital financing led by OMERS Ventures. The investment, one of the largest Series A financings in the Canadian tech industry, included Infinite Potential Technologies, Real Ventures, BDC IT Venture Fund, RBC, Manulife Financial, and Power Financial Corporation.
- Represented Cinven in its $3.5 billion (£2.3 billion) sale of Amdipharm Mercury Company Limited to Concordia Healthcare Corp.Represented Nordion in the $200 million sale of TheraSphere®, its targeted therapies division, to BTG plc.
- Advised Tandem Expansion Fund in its subscription in Blueprint Software Systems, Inc.'s private placement of Class B convertible preferred shares.
Other Experience:
- Advised Thornhill Medical in negotiating manufacturing and supply agreements to make and deliver mobile compact ventilator systems as part of the Canadian government's response to fight COVID-19.
- Advised OmniaBio in connection with its launch, including its spinout from the Centre for Commercialization of Regenerative Medicine (CCRM), its C$30 million sale of a 39% interest to Medipost Co., C$40 million in government funding by the Government of Ontario, and up to C$100 million convertible note financing and the negotiation of its new C$580 million cell and gene therapy facility.
- Advised Conavi Medical in its exclusive distribution agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Ltd. in connection with the sale of its Foresight™ Intracardiac Echocardiography (ICE) and Novasight™ Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan, and Macau.
- Advised Colibri Technologies (now Conavi Medical Inc.) in an exclusive distribution agreement with Japan Lifeline Co., Ltd. for the distribution of Colibri’s intracardiac echocardiography imaging system in Japan.
Read less
News & Press
Mintz Announces Record Member Growth in 2023
December 22, 2023
Mintz proudly announced the election of 13 attorneys to Members and the addition of a record-setting 22 new lateral Members in 2023, with 11 Partners in the newly opened Toronto office. This diverse group strengthens Mintz’s core areas, spanning Commercial and IP Litigation, Life Sciences, Tech, Private Equity, and Energy & Sustainability. The elevated Members and new lateral additions bring invaluable expertise to help clients navigate complex legal landscapes.
High-Profile Toronto Real Estate Attorney Joins Mintz
December 18, 2023
TORONTO – Mintz continues its expansion in Toronto with the addition of Mervyn Allen who joins as a Partner and will launch the firm’s Real Estate practice in Canada.
Mintz Adds Strength To Cross-Border Corporate Practice
September 25, 2023
TORONTO – Mintz is set to further enhance its Debt Financing practice with the addition of Alex North, who joins as a Partner and will bolster the firm’s US and Canadian capabilities.
Mintz Signs Sublease For Toronto Office
April 17, 2023
TORONTO – Mintz is pleased to announce that it has subleased the 28th floor at 200 Bay Street’s South Tower, an iconic pillar of Toronto's Financial District. The firm moved into the nearly 24,000 square feet of space on April 1, 2023.
Mintz Continues To Expand Leading Life Sciences And Private Equity Capabilities In Toronto
April 12, 2023
TORONTO – Mintz continues to grow in Canada and extend its market-leading life sciences and private equity capabilities. The addition of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie, will bolster Mintz’s premier capital markets, M&A, funds, and employment and pensions-focused practices.
Mintz Adds To Life Sciences, PE Team In Toronto
April 12, 2023
The arrival of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie was covered by The Deal. The article stated, "The new attorneys strengthen the firm’s life sciences and private equity capabilities in its Toronto office."
Mintz Continues Bay Street Legal Talent Raid, Hiring Four Lawyers From Torys, Dentons
April 12, 2023
The Globe and Mail featured the arrival of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie who will join Michael Akkawi, Cheryl Reicin, Mitch Frazer, Eric Foster, and Lee Johnson in the firm's Toronto office.
Law.com covered the arrival of Toronto Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie.
Recent Insights
Mintz proudly announced the election of 13 attorneys to Members and the addition of a record-setting 22 new lateral Members in 2023, with 11 Partners in the newly opened Toronto office. This diverse group strengthens Mintz’s core areas, spanning Commercial and IP Litigation, Life Sciences, Tech, Private Equity, and Energy & Sustainability. The elevated Members and new lateral additions bring invaluable expertise to help clients navigate complex legal landscapes.
TORONTO – Mintz continues its expansion in Toronto with the addition of Mervyn Allen who joins as a Partner and will launch the firm’s Real Estate practice in Canada.
TORONTO – Mintz is set to further enhance its Debt Financing practice with the addition of Alex North, who joins as a Partner and will bolster the firm’s US and Canadian capabilities.
